Page 67 - MI-2-3
P. 67

Microbes & Immunity                                       Understanding lung development, health, and diseases



            72.  Takahashi Y, Saito A, Chiba H, et al. Impaired diversity of   administration of  Lactobacillus  casei shirota on influenza
               the lung microbiome predicts progression of idiopathic   virus infection of upper respiratory tract in mice. Clin Diagn
               pulmonary fibrosis. Respir Res. 2018;19:34.        Lab Immunol. 2001;8:593-597.
               doi: 10.1186/s12931-018-0736-9                     doi: 10.1128/CDLI.8.3.593-597.2001
            73.  Tiwari SK, Dicks LM, Popov IV,  et al. Probiotics at war   79.  Okwor VC, Okwor CJ, Musayayi SA,  et  al. Immune
               against viruses: What is missing from the picture?  Front   modulation and epigenetic therapies for enhanced outcome
               Microbiol. 2020;11:1877.                           of treatment in triple-negative breast cancer. Tumor Discov.
                                                                  2024;3(3):3383.
               doi: 10.3389/fmicb.2020.01877
                                                                  doi: 10.36922/td.3383
            74.  Kurian SJ, Unnikrishnan MK, Miraj SS, et al. Probiotics in
               prevention and treatment of COVID-19: Current perspective   80.  Allis C, Jenuwein T. The molecular hallmarks of epigenetic
               and future prospects. Arch Med Res. 2021;52:582-594.  control. Nat Rev Genet. 2016;17(8):487-500.
               doi: 10.1016/j.arcmed.2021.03.002                  doi: 10.1038/nrg.2016.59
            75.  Khatiwada S, Subedi A. Lung microbiome and coronavirus   81.  Angrish MM, Allard P, McCullough, SD, et al. Epigenetic
               disease 2019 (COVID-19): Possible link and implications.   applications  in  adverse  outcome  pathways  and
               Hum Microb J. 2020;17:100073.                      environmental risk evaluation.  Environ Health Perspect.
                                                                  2018;126(4):045001.
               doi: 10.1016/j.humic.2020.100073
                                                                  doi: 10.1289/EHP2322
            76.  Harata G, He F, Hiruta N, Kawase M, Kubota A,
               Hiramatsu  M, Yausi H.  Intranasal administration of   82.  Leblanc C, Baron M, Desselas E,  et al. Congenital
               Lactobacillus  rhamnosus GG  protects  mice  from H1N1   pulmonary  airway malformations: State-of-the-art review
               influenza virus infection by regulating respiratory immune   for pediatrician’s use. Eur J Pediatr. 2017;176(12):1559-1571.
               responses. Lett Appl Microbiol. 2010;50:597-602.     doi: 10.1007/s00431-017-3032-7
               doi: 10.1111/j.1472-765X.2010.02844.x           83.  Beers M, Morrisey E. The three R’s of lung health and
            77.  Jung YJ, Lee YT, Ngo VL,  et al. Heat-killed  Lactobacillus   disease: Repair, remodeling, and regeneration. J Clin Invest.
               casei confers broad protection against influenza a virus   2011;121:2065-2073.
               primary infection and develops heterosubtypic immunity      doi: 10.1172/JCI45961
               against future secondary infection. Sci Rep. 2017;7:17360.
                                                               84.  Schmidt  TSB, Raes J, Bork  P. The human  gut microbiome:
               doi: 10.1038/s41598-017-17487-8                    From association to modulation. Cell. 2018;172(6):1198-1215.
            78.  Hori T, Kiyoshima J, Shida K, Yasui H. Effect of intranasal      doi: 10.1016/j.cell.2018.02.044


































            Volume 2 Issue 3 (2025)                         59                               doi: 10.36922/mi.7719
   62   63   64   65   66   67   68   69   70   71   72